Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIT-P
NCT07660172Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Feb 2027
- Primary completion
- Apr 2033
01
Overview
Phase 2, open-label, single-arm trial of ianalumab in primary immune thrombocytopenia (ITP), sponsored by Novartis. Primary endpoint: Time to treatment failure up to 39 months. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
ianalumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07660172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660172.